ClinicalTrials.gg
Active, not recruitingNCT05984277eVOLVE-Lung02Updated Oct 9, 2026

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

A Phase 3 interventional study of Volrustomig and Pembrolizumab in Metastatic Non-small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 231 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 9, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
895
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 25 open to participants now, 78 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Enrollment
12th of 137
895 · median 152
Started
2023
with 8 others
Phase 3
44 of 209
6 open now
Primary completion
2026-08
later than 34 of 77 live
Registered
173rd of 209
by date

Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 12th largest by enrollment of the 137 interventional ones that give a count, is one of 9 that started in 2023, is one of 44 in phase 3, reaches primary completion later than 34 of the 77 other live ones, and was the 173rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

25 of the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.

Read the detailed description

Adult patients with a histologically or cytologically documented metastatic NSCLC, with tumors that lack activating EGFR, ALK, and ROS1 alterations are eligible for enrollment. Patients will be randomized in a 1:1 ratio to receive treatment with volrustomig + chemotherapy or pembrolizumab + chemotherapy. Tumor evaluation scans will be performed until disease progression as efficacy assessment. All patients will be followed for survival until the end of the study. An data monitoring committee (DMC) composed of independent experts will be convened to confirm the safety and tolerability of the proposed dose and schedule.

03

Conditions studied

  • Metastatic Non-small Cell Lung Cancer

Keywords

  • metastatic non-small cell lung cancer
  • non-squamous tumors
  • squamous tumors
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically documented squamous or non-squamous NSCLC.
  • Stage IV NSCLC (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology 2016), not amenable to curative surgery or radiation.
  • Absence of sensitizing EGFR mutations and ALK and ROS1 rearrangements.
  • Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted therapies.

Key Exclusion Criteria:

  • Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant. Rare subtypes are excluded.
  • Spinal cord compression.
  • Symptomatic . Brain metastases may be treated or untreated, but participants must be asymptomatic and off for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of brain radiotherapy and study enrollment.
  • History of another primary except for:

    1. Malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence.
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    3. Adequately treated carcinoma in situ without evidence of disease.
  • As judged by the investigator, any condition that would interfere with evaluation of the study intervention or interpretation of participant safety or study results.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
895 participants (actual)

Study arms

  • Experimental
    Arm 1

    Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion

    Drug: Volrustomig · Drug: Carboplatin · Drug: Paclitaxel · Drug: Pemetrexed

  • Active comparator
    Arm 2

    Pembrolizumab plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion

    Drug: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Pemetrexed

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)

    PFS is defined as the time from randomization until radiological progression per RECIST 1.1 as assessed by BICR, or death due to any cause (in the absence of progression), in PD-L1-negative participants.

    Time frame: Up to approximately 6 years

  2. Overall Survival (OS), in PD-L1-negative participants.

    OS is defined as the time from randomization until the date of death due to any cause, in PD-L1-negative participants.

    Time frame: Up to approximately 6 years

Secondary outcomes

  1. PFS (using BICR assessments according to RECIST 1.1)

    PFS is defined as the time from randomization until radiological progression per RECIST 1.1 as assessed by BICR, or death due to any cause (in the absence of progression). The analysis will include all randomized participants.

    Time frame: Up to approximately 6 years

  2. OS

    OS is defined as the time from randomization until the date of death due to any cause. The analysis will include all randomized participants.

    Time frame: Up to approximately 6 years

  3. PFS (using Investigator assessments according to RECIST 1.1)

    PFS is defined as the time from randomization until radiological progression per RECIST 1.1 as assessed by investigator, or death due to any cause (in the absence of progression).

    Time frame: Up to approximately 6 years

  4. Overall Response Rate (ORR)

    ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by BICR assessments using RECIST 1.1.

    Time frame: Up to approximately 6 years

  5. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response until the date of documented progression per BICR assessments using RECIST 1.1 or death due to any cause (in the absence of progression). These analyses will include participants who have a confirmed response.

    Time frame: Up to approximately 6 years

  6. PFS2

    PFS2 is defined as the time from randomization until the earliest of the progression event (following the initial investigator-assessed progression) after the start of the first subsequent therapy, or death. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice.

    Time frame: Up to approximately 6 years

  7. Concentration of volrustomig in serum and PK parameters

    To assess the PK of volrustomig

    Time frame: Up to approximately 6 years

  8. Presence of ADAs against volrustomig in serum

    To investigate the immunogenicity of volrustomig.

    Time frame: Up to approximately 6 years

  9. Time-To-Deterioration (TTD) in physical functioning

    To assess participant-reported physical functioning in participants treated with volrustomig plus chemotherapy and pembrolizumab plus chemotherapy.

    Time frame: Up to approximately 6 years

  10. TTD of lung cancer symptoms

    To assess participant-reported pulmonary symptoms of mNSCLC in participants treated with volrustomig plus chemotherapy and pembrolizumab plus chemotherapy.

    Time frame: Up to approximately 6 years

07

Study locations

231 sites
  • Research Site
    Hot Springs, Arkansas 71913, United States
  • Research Site
    Springdale, Arkansas 72762, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Lone Tree, Colorado 80124, United States
  • Research Site
    Orlando, Florida 32827, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Des Moines, Iowa 50309, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Grand Island, Nebraska 68803, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    East Syracuse, New York 13057, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Horsham, Pennsylvania 19044, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Memphis, Tennessee 38104, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Nashville, Tennessee 37212, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Irving, Texas 75063, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    CABA, 1425, Argentina
  • Research Site
    CABA, C1061, Argentina
  • Research Site
    CABA, C1425, Argentina
  • Research Site
    Córdoba, 5000, Argentina
  • Research Site
    Córdoba, X5800HHW, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    La Plata, B1900AVG, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Fitzroy, 3065, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Sydney, NSW 2145, Australia
  • Research Site
    Linz, 4021, Austria
  • Research Site
    Wels, 4600, Austria
  • Research Site
    Aalst, 9300, Belgium
  • Research Site
    Antwerp, 2020, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Curitiba, 80730-150, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Fortaleza, 60336-045, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90619-900, Brazil
  • Research Site
    Porto Alegre, 91350200, Brazil
  • Research Site
    Rio de Janeiro, 22281-100, Brazil
  • Research Site
    Santa Cruz do Sul, 96810-110, Brazil
  • Research Site
    São Paulo, 01221-020, Brazil
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Winnipeg, Manitoba R3E 0V9, Canada
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    Barrie, Ontario L4M 6M2, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Lévis, Quebec G6V 3Z1, Canada
  • Research Site
    Trois-Rivières, Quebec G8Z 3R0, Canada
  • Research Site
    Chicoutimi, G7H 5H6, Canada
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 101149, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chengdu, 611135, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Fuzhou, 350011, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Hangzhou, 310020, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Lanzhou, 730000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanchang, 330008, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Shenzhen, 518116, China
  • Research Site
    Taiyuan, 030000, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Xi'an, 710000, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Olomouc, 77900, Czechia
  • Research Site
    Ostrava - Vitkovice, 703 84, Czechia
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Angers, 49055, France
  • Research Site
    Avignon, 84902, France
  • Research Site
    Bayonne, 64100, France
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Caen, 14033, France

Showing the first 100 of 231 sites across 25 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. SignedData Sharing Agreement (non-negotiable contract for data accessors) must be inplace before accessing requested information. Additionally, all users will need toaccept the terms and conditions of the SAS MSE to gain access. For additionaldetails, please review the Disclosure Statements athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Aug 2026, 33 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 33 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Feb 2029 → Aug 2026 and completion Feb 2029 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2023
First posted
Aug 9, 2023
StartActual
Oct 24, 2023
Primary completionActual
Aug 17, 2026was Feb 2029
CompletionEst.
Nov 12, 2027was Feb 2029
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
16 sites removed
Show 16 removed
  • Research Site · Fort Myers, United States
  • Research Site · West Palm Beach, United States
  • Research Site · Fort Wayne, United States
  • Research Site · Lexington, United States
  • Research Site · Louisville, United States
  • Research Site · Annapolis, United States
  • Research Site · Silver Spring, United States
  • Research Site · Fresh Meadows, United States
  • Research Site · Columbus, United States
  • Research Site · Dayton, United States
  • Research Site · Lancaster, United States
  • Research Site · Beijing, China
  • Research Site · Hefei, China
  • Research Site · Linhai, China
  • Research Site · Linyi, China
  • Research Site · Groningen, Netherlands
Oct 9, 2026
Primary completion
Feb 28, 2029→Aug 17, 2026 (actual)
Oct 9, 2026
Study completion
Feb 28, 2029→Nov 12, 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    16 sites removed
    Show 16 removed
    • Research Site · Fort Myers, United States
    • Research Site · West Palm Beach, United States
    • Research Site · Fort Wayne, United States
    • Research Site · Lexington, United States
    • Research Site · Louisville, United States
    • Research Site · Annapolis, United States
    • Research Site · Silver Spring, United States
    • Research Site · Fresh Meadows, United States
    • Research Site · Columbus, United States
    • Research Site · Dayton, United States
    • Research Site · Lancaster, United States
    • Research Site · Beijing, China
    • Research Site · Hefei, China
    • Research Site · Linhai, China
    • Research Site · Linyi, China
    • Research Site · Groningen, Netherlands
    Primary completion Feb 28, 2029→Aug 17, 2026 (now actual)
    Study completion Feb 28, 2029→Nov 12, 2027
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05984277
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
Oct 24, 2023
Primary completion
Aug 17, 2026
Completion
Nov 12, 2027 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Volrustomig

Start the discussion